Today: 20 March 2026
Subscribe
Browse Category

NYSE:MOH 23 October 2025 - 9 March 2026

Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum shares rose 10.6% to $617.81 in New York trading after S&P Dow Jones Indices said it will add the company to the S&P 500 on March 23. The move follows Nvidia’s $2 billion investment and a multiyear purchase agreement announced last week. Peers Coherent and Vertiv also gained. Lumentum reported second-quarter revenue up 65.5% to $665.5 million and forecast third-quarter revenue of up to $830 million.
9 March 2026
···········
UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth shares rose 0.3% to $277.44 in late morning trading Monday after CMS signaled a 0.09% Medicare Advantage payment increase for 2027. The stock remains under pressure after a 19% drop on Jan. 27, when the company warned of its first revenue decline since 1989. U.S. stocks were mixed, with the Dow down 0.3%. Comments on the CMS proposal are due by Feb. 25.
9 February 2026
··
Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Molina Healthcare plunged 25.5% after forecasting 2026 profit far below estimates and announcing a 2027 exit from Medicare Part D. Centene guided profit above expectations but dropped 3.7%, while Cigna rose 2.6% on a strong quarter but flagged a softer 2026 outlook. XLV gained 1.8%. Hims fell 10% after the FDA warned against mass-marketing compounded obesity drugs.
7 February 2026
···
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

The Dow Jones Industrial Average closed above 50,000 for the first time Friday, ending at 50,115.67, up 2.47%. Nvidia surged 7.8% as chip stocks rallied on AI spending hopes, while Amazon dropped 5.6% after projecting $200 billion in 2026 capital expenditures. Traders await delayed U.S. jobs and inflation reports next week.
6 February 2026
····
Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare shares plunged 27% to $129.77 after the company forecast 2026 adjusted EPS of at least $5.00, far below the $13.76 analyst consensus. Management cited higher medical costs and a sharp pullback in ACA Marketplace membership. The company posted a Q4 adjusted loss of $2.75 per share and plans to exit its Medicare Advantage Part D business in 2027.
6 February 2026
·
Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health shares fell 2.3% to $12.22 in premarket trading Friday after a 5.4% drop Thursday, as investors reacted to Molina Healthcare’s profit warning and exit from Medicare Part D. Molina’s stock plunged nearly 35% after hours, dragging other managed-care stocks lower. Oscar reports earnings Feb. 10, with investors watching for updates on 2026 enrollment and claims.
6 February 2026
····
Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare shares traded near $169.53 on Dec. 12, 2025, following an eighth straight session of gains. The stock’s rebound comes after a steep drop earlier in the year, with shares still well below the April high of $359.97. A new diabetes care partnership in South Carolina and renewed ACA policy uncertainty have influenced recent trading.
12 December 2025
·
MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

Molina Healthcare shares closed up 2.6% at $145.30 Monday on heavy volume after reports of a possible extension of ACA subsidies. The stock remains down over 50% from its 52-week high following an October earnings shock and ongoing class-action lawsuits. Market cap stood at $7.5 billion, with a P/E ratio near 9x. Intraday trading ranged from $141 to $151.
24 November 2025
·

Stock Market Today

  • Cintas (CTAS) Share Pullback Prompts Valuation Reassessment Amid Sector Focus
    March 20, 2026, 5:59 AM EDT. Cintas shares have fallen 5.9% over the past week and 6.7% in 30 days, prompting questions about value at the current $181.83 price. Despite a 1.6% year-to-date dip, three-to-five year returns are strong at 72.4% and 125.9%. Investors are scrutinizing pricing, contract quality and cost control in service providers, affecting sector valuations. Cintas scores 0 out of 6 on valuation metrics. A discounted cash flow (DCF) analysis estimates a fair value near $177.18 per share, suggesting shares are about 2.6% overvalued, a margin within typical model error. The company's price-to-earnings (P/E) ratio stands at 38.45x, above the industry average of 22.80x and peer group average of 33.33x, indicating elevated market expectations. Investors should monitor valuation indicators closely given these mixed signals.
Go toTop